The CGRP anti-migraine prophylaxis drug erenumab (Aimovig) has had its application for listing on the PBS withdrawn by manufacturer Novartis. The company said it had decided not to proceed with a third erenumab submission to the Pharmaceutical Benefits Advisory Committee (PBAC) after being rejected twice for a listing for prevention of migraine It said erenumab ...
Erenumab manufacturer drops bid for PBS listing
By Michael Woodhead
30 Oct 2019